Search the Newsreel

Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax

Latigo Biotherapeutics plans an IPO to fund its non-opioid pain drug pipeline, including late-stage studies for LTG-001, an oral small-molecule Nav1.8 inhibitor. The company aims to compete with Vertex Pharmaceuticals' Journax, highlighting potential advantages in efficacy and administration. Latigo has already secured significant Series …

Is Arrowhead Pharmaceuticals (ARWR) Undervalued Or Is Its Pipeline Promise Already Priced In?

Arrowhead Pharmaceuticals (ARWR) has seen recent stock volatility, with a 4.1% gain in the past day but an 8.3% drop over the last month, yet a strong 1-year return. Analysts view the stock as undervalued with a fair value of $89.08 against its current …

Will Pediatric Casgevy Expansion and Canadian ALYFTREK Talks Change Vertex Pharmaceuticals' (VRTX) Narrative?

U.S. regulators recently expanded approval of Vertex Pharmaceuticals' gene-editing therapy Casgevy for pediatric patients as young as 2 years old. Concurrently, Canada's pan-Canadian Pharmaceutical Alliance has initiated discussions for public reimbursement of Vertex's cystic fibrosis therapy ALYFTREK. These developments are viewed as crucial for …

Can Catalyst Pharmaceuticals (CPRX) Keep Looking Fairly Valued Now?

Catalyst Pharmaceuticals stock has seen a significant 4.6x return over the past five years, yet its current valuation appears to be roughly in line with its fundamentals rather than being clearly cheap or overvalued. The company's P/E ratio of 17.4x is close to its …

Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains

Shares of Vertex Pharmaceuticals Inc. (VRTX) rose 1.88% on Thursday, closing at $486.03. Despite this gain, the stock underperformed the broader market, with the S&P 500 Index falling 0.51% and the Dow Jones Industrial Average dropping 0.20%. This marks the second consecutive day of …

Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85 per share in an all-cash deal, valuing the acquisition at approximately $10 billion. The boards of both companies have unanimously approved the transaction, which is expected to close in Q3 of this year. …

Vertex Pharmaceuticals Stock Slides 10% Over 6 Straight Down Days

Vertex Pharmaceuticals (VRTX) stock has experienced a significant decline, falling 10.1% over six consecutive trading days, resulting in a $14 billion loss in market value. While the company exhibits strong fundamentals with higher-than-median revenue growth and operating margins compared to the S&P 500, its …

Vertex (VRTX) Is Buying Crinetics For $10 Billion To Enter Adrenal Disease

Vertex Pharmaceuticals (VRTX) is acquiring Crinetics Pharmaceuticals in a US$10 billion all-cash transaction, marking its entry into adrenal disease therapeutics. This acquisition includes atumelnant, a late-stage clinical drug candidate for congenital adrenal hyperplasia. The deal is significant as it broadens Vertex's pipeline beyond its …

Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals (CRNX) in a cash deal valuing Crinetics at approximately $10 billion, or $85 per share. Crinetics' stock has surged recently, with strong momentum leading up to the acquisition news. While the stock currently trades just below …

Vertex is almost back at its 52-week peak as volume normalises after the 15.0M-share push

VRTX added 7.5% in the latest week and closed just 0.2% below its 52-week high, but the Sharemaestro read remains balanced because the weekly Trend Signal is still inactive and participation has returned to baseline.

VRTX Prognose — Kursziel für 2027

Vertex Pharmaceuticals Stock: Q1 2026 Revenue Hits $2.99B With Full-Year Guidance Intact

Vertex Pharmaceuticals Stock Pops 5% On Successful Late Stage Kidney Disease Drug Trial